New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
17:37 EDTICPTIntercept Pharmaceuticals initiates Phase 2 NASH tiral of OCA in Japan
Intercept Pharmaceuticals announced that its partner Dainippon Sumitomo Pharma, or DSP, has initiated a phase 2 clinical trial of obeticholic acid, or OCA, in adult nonalcoholic steatohepatitis, or NASH, patients in Japan. The trial is studying the efficacy and safety of a once daily dose of OCA, with the goal of randomizing 200 NASH patients to receiving OCA or placebo. The primary endpoint will be evaluated by histological improvement. DSP expects to complete the trial in the first half of 2016.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2015
14:24 EDTICPTIntercept, Keryx fall after Morgan Stanley starts with sell ratings
Subscribe for More Information
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:26 EDTICPTIntercept initiated with an Underweight at Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use